Keywords: medarex, full-year, loss, narrows, drugmaker, says, its
Medarex' full-year 2005 loss narrows 28%
Article | 13 March 2006
US drugmaker Medarex says that its net loss for the year ended December 31, 2005, was $146.0 million, or $1.32 per share, versus $186.5 million, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
